Biophytis Sa · EURONEXT:ALBPS
Biophytis Sa — Investor Presentation (June 2022)
10 slides from Biophytis Sa's investor presentation, Jun 3, 2022
Slide 1: Paris, 3 June 2022
Paris, le 3 juin 2022 I Euronext : ALBPS – Nasdaq : BPTS
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential
Slide 3: Today's Corporate Highlights
Today’s Corporate Highlights Biophytis SA HQ location: Paris, France • Is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes Founded: 2006 associated with aging. • Our small molecules are aimed at stimulating bio
Slide 4: Our Clinical Pipeline as of today
Our Clinical Pipeline as of today Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3 Covid-19 COVA Sarconeos Sarcopenia (BIO101) Duchenne Muscular Dystrophy Dry AMD Macuneos (BIO201) Stargardt XXX : orphan diseases 4
Slide 5: Our strategic objectives
Our strategic objectives STRENGTHEN OUR PRESENCE IN THE UNITED STATES, DEVELOP A PORTFOLIO OF DRUG CANDIDATES IN AGE-RELATED DISEASES, IN PARTICULAR MUSCULAR AND THE LEADING BIOTECH/PHARMA MARKET OPHTHALMOLOGICAL DISEASES • Develop the company in the United States, in particular its clinical, regula
Slide 6: Consolidation of our scientific expertise and strengthening of industrial property
Consolidation of our scientific expertise and strengthening of industrial property RECOGNIZED SCIENTIFIC EXCELLENCE A STRONGER PATENT PORTFOLIO 9 scientific publications in peer-reviewed journals in 2021 • A portfolio of 15 patent families – in total 48 • Publications describing the mechanism of act
Slide 7: Strengthening of the company's fundamentals over the past 18 months
Strengthening of the company's fundamentals over the past 18 months VALIDATIONS OF THE THERAPEUTIC POTENTIAL OF SARCONEOS (BIO101) STRENGTHENING OF THE FINANCIAL STRUCTURE (Nasdaq IPO) COVA Study – COVID-19 • Part 2 interim analysis achieved in Q3 2021with positive DMC review to finalise the study w
Slide 8: Growth in R&D costs and healthy financial situation
Growth in R&D costs and healthy financial situation In €M 2020 2021 Research and developement expenses, net (9.9) (19.7) General and administrative expenses (4.0) (7.1) Operational loss (13.9) (26.8) Net financial expense (11.6) (4.4) Loss before taxes (25.5) (31.2) Net loss (25.5) (31.2) In €M Dec.
Slide 9: Key milestones in the development of Sarconeos (BIO101)
Key milestones in the development of Sarconeos (BIO101) Achieved over the last 12 months Anticipated in the next 12 months • Interim analysis for Part 2 (155 patients) in Q3 2021 • Phase 2/3 study results expected in Q3 2022 COVA • Early Access Program (EAP) authorization in Brazil in February 2022
Slide 10: Thank you
Thank you Contact investisseurs : investors@biophytis.com 10